The News Net


In this week’s Net: a stem cell roadmap for India, more money for early stage biotech in Quebec and a word on the debate of the moment from Bruce Booth.

 

  • At a recent stem cell and regenerative medicine conference, India’s former president A.P.J. Abdul Kalam said the department of biotechnology and the Indian Council of Medical Research would soon come out with a roadmap for stem cell research and therapy. “They are evolving a road map for stem cell research through three areas—adult stem cells, umbilical cord stem cells, and embryonic stem cells.” More here.
  • According to the Montreal Gazette, Merck has partnered with two Canadian VCs to launch the Merck Lumina Biosciences Fund to invest in early-stage biotech firms in Quebec. The drugmaker is committing $35 million to the fund’s $50 million target. Read more here.
  • In Forbes, VC & blogger Bruce Booth gives his take on the hot topic of biotech business models: what’s in, what’s out and what’s dead. Find out what your “worldview” is here.

International Business Development in Africa

Africa is the world’s second largest and second most populous continent, comprising more than 54 countries. With a population of over 1 billion, it is attractive for any investor. Being successful in these markets requires insight into the languages, cultures, government bureaucracy, regulations, type of innovative technologies and workforce of each country. Every one is different, and this makes it very difficult to use the same recipe for any two countries.  There may be similarities in the regions but inside information is still required.

As a result of colonialism, many African countries inherited European languages. In addition to these languages, there are many national languages that are spoken. For example, French is the dominant language in Central Africa, while English is dominant in Western, Eastern and Southern African countries. North of Africa, in addition to English you can survive if your Arabic is good.  There is also Portuguese spoken in Angola, Mozambique and Equatorial Guinea.  This makes it a rainbow continent. The language barrier can be seen clearly in the type of investments made in these countries, French pharmaceutical companies feel more comfortable establishing themselves in French-speaking countries.  This paradigm is gradually changing as people begin to understand the culture and language of these countries.  South Africa is learning fast in this area and taking the lead in penetrating the African market. This is done by hiring locals who can speak the language to be part of the development or management team.

If you consider culture to be an integrated pattern of human knowledge and beliefs, as well as a set of shared attitudes, values, goals, and practices that characterize a group of people, then Africa is a continent with diverse culture. This should be seen as an opportunity for any investor. Certain countries in Africa are very particular about the clothes that they wear. The religion practiced by the people in the country allows the women to dress in certain attire, and cotton is the most preferred and affordable clothing material. Thus, the introduction of genetically modified cotton in South Africa and Burkina Faso will not only increase the cotton production but will also revive these industries that are competing with cheap imported materials. Another interesting development in the agriculture sector is the emergence of different types of farmers. The younger farming generation would prefer early maturing, high-yielding food crops that are resistant to environmental and biological stress factors. This is simply because they want to make money fast, therefore, seed companies should  be aware of this new trend.  In general, only companies that know what their customers want will grow and expand fast in Africa.

Government bureaucracy and regulations: This is an area in Africa where every country has its own governance model. This normally confuses investors and is one of the biggest hurdles to jump, though some African countries are putting systems in place to make it easy for an investor.  It is now clear that for unemployment to be lowered in African countries, Small Medium and Micro Enterprises (SMMEs) have to be encouraged and fully supported by governments. In the ’80s and early ’90s, the government in many African countries was the major employer. African countries have realized that there is a limit to the number of jobs that could be given by the government and are now encouraging SMMEs. This is good for economic growth; however, they have not learnt how to remove the hurdles for investors.

Investors prefer a soft landing or reward (tax holidays, tax loss, tax incentives for the initial period especially for SMMEs, favourable exchange laws) to make the country attractive to invest.  Regulations are good but the bar on meeting these regulations do not have to be cumbersome. This at times is a bottleneck in selecting a country for investment. In the biotech sector, countries like Kenya, South Africa and Egypt will benefit in the agriculture and pharmaceutical industries, because they have started putting in place policies that are attractive to investors.

Another positive is that Africa embraces technology without fear.  The cell phone has revolutionized the African market. Novel biotechnology food products are widely accepted.  South Africa is one of the most technological-advanced countries in Africa and it is successful in selling its products to Africa because they can produce and sell at affordable prices and the quality is high. Africans do not compromise on quality, contrary to what some investors think.  The salary range in Africa is normally divided into three categories: high, middle and low income class.  In many African countries, the buying population normally falls within the middle income class, and this is usually the young generation who normally desires innovative technologies. As an investor, you must know and understand the target group that you will like to sell your products.

Blessed Okole

Will work for cash

Three years ago, at the 3rd Plant-Based Vaccines & Antibodies meeting in Verona , I proposed what I thought was a novel idea to move the field of “pharming” forward.  With Andres Wigdorovitz from Buenos Aires in Argentina, I suggested that companies in the USA and Europe could advance their recombinant plant-produced biologicals product development very significantly by investing in research groups in countries like Argentina and South Africa, where the science was essentially on par with northern countries, but personnel and facilities cost far less.  Moreover, the regulatory and ethical frameworks are often as sophisticated as those of developed countries, and according to the most recent annual report of the International Service for the Acquisition of Agribiotech Applications (ISAAA), in fact developing countries are among the leading proponents of the use of GM plants.

Seriously: of the ten countries growing more than 1 million hectares of GM crops in 2011, seven are developing nations – and six of the ten are in the Americas, with Brazil second to the USA, followed by Argentina, India and Canada.  South Africa comes in ninth, ahead of Australia at 12.

Continue reading

And Algae Shall Inherit the Earth

In October, I touched on the promise of biofuels as part of a larger revolution in consumer biology. The recent emergence of biofuels on the political agenda is worthy of note. It is clear that the world’s dependence on fossil fuel is strained on two fronts: the projection that global supplies will eventually run out, and the need to reduce greenhouse emissions and alter the course of global warming.

The world’s largest user of fossil fuels is the United States, mostly for transportation fuel. Therefore, changes to the way that the US uses fossil fuels and any moves to use alternatives are highly significant drivers to the alternative fuels market. Recently, there has been three key developments, all driven by the US, that have created a ‘perfect storm’ of opportunity for strategically placed companies, including well-positioned start-ups.

Firstly, the US Environmental Protection Agency’s new set of Renewable Fuel Standard (RFS) regulations requiring 36 billion gallons of renewable fuel to be blended into gasoline and diesel by 2022. Secondly, regulations due to start in 2015 will require all ships operating within a US designated area, called the Emissions Control Area (an area that includes Canada, Alaska, the US Virgin Islands, and Puerto Rico), to use fuel with less than 0.1% sulfur content (1,000 parts per million). Essentially, opening up the potential for cruise operators and others to now seriously consider using biofuels. Thirdly, and most significantly, the news from last August that the Departments of Energy, Defense, and Agriculture will commit $510 million to build a viable biofuels industry able to provide half of the US Navy’s fuel needs by 2020 – a staggering 5 billion gallons each year. This last measure is born from both strategic and economic needs. The cost of a barrel of oil continues to rise and the Straits of Hormuz is growing more vulnerable in a political game of chess.

Continue reading

The News Net

For your reading pleasure, this week’s News Net brings in investment news from Russia, agbiotech in the Philippines and advice on handling your board from the hardest working VC in the blogosphere.

 

 

  • Government-owned RusNano is partnering with US venture firm Domain Associates on a $760 million initiative that will invest in about 20 life sciences companies and construct a pharma manufacturing center in Russia to produce next-gen therapies. The two groups plan to concentrate on viral infections, cardiovascular diseases, cancer and other afflictions. Read all about it here.
  • The Philippine Star reports on the commercial production of locally developed agbiotech products. Mature technologies developed by the University of the Philippines Los Baños include biofertilizers, enzymes, pesticides, animal probiotics, and plant disease diagnostic kits. Dig in here.
  • In Forbes, life science VC and Trade Secrets blogger Bruce Booth (https://blogs.nature.com/tradesecrets/author/bbooth) looks at what it takes to maintain a highly functional and productive board of directors – crucial for an early-stage biotech company. Read his tips here.  You can also follow him on Twitter.

 

A View from India

We’re adding a new member to Trade Secrets’ author roll: Ian Scoones.  He’s been blogging on aspects of India’s biotech scene and is going to contribute new content for Trade Secrets going forward.

In the meantime, you’ll find links to some of his previous writing below.

  • To read Seminar: What happened to biotech in Bangalore? go here.
  • For Biotech business in Bangalore: a decade of hype and hope? visit this link here.
  • And for Getting Hotter – Regulating Biotechnology, place your mouse (or finger, depending on how you are reading this) here.

BoPping and MoPping

I recently read a report on how private sector companies and grant-supported organizations have addressed and can address the need for medicines in bottom and middle-of-the-pyramid (BoP/MoP) markets.  While aimed at the major international pharma companies, I thought it also had useful guidance and resources for bioentrepreneurs.  The report, “Bringing Medicines to Low Income Markets,” was sponsored by the German Federal Ministry of Economic Cooperation and Development (BMZ) and Sanofi, and written by Endeva, a consulting firm offering “enterprise solutions for development.”  The report starts with a helpful and succinct description of the BoP/MoP healthcare market’s opportunities and challenges.  Here’s my summary of the salient points made:

 

  • the demand (need) is large with 1.7 billion people lacking access to the basic, essential medicines and another 2.3 billion with limited access;
  • while the annual household income of these 4 billion is under $3,000, they spend about $160 billion on healthcare, about one-third of which is on pharmaceuticals;
  • drugs are 2-6 times more expensive in the under-served markets than in developed markets due to taxes/tariffs, middleman mark ups, and supply (inventory) problems;
  • in lower-income countries communicable (infectious) and non-communicable diseases (NCDs, such as diabetes, heart disease, cancer) contribute equally to a country’s mortality rate, while in middle-income countries the NCDs contribute more than twice as much as the communicable diseases; and
  • companies seeking to enter the low-income markets are challenged by missing “enablers” such as the lack of doctors and other trained health practitioners, regulations (in many countries 20-30% of the drugs sold are counterfeit), infrastructure for delivery and stocking of products, financing for businesses providing health care, and insurance plans (70% of low-income patient drug purchasing is out-of-pocket).

Continue reading

Multipotent scientists survive in tough times

It’s not always sunny for start-ups in healthcare biotech. And when the weather gets bad, one should either go dormant or find places with the right climate.  We can learn this lesson from Prof. Yuichi Mori and Dr. Hiroshi Yoshioka, the polymer-biology duo from Waseda University, Japan.

When Yuichi Mori set up his lab for polymerization-related work in Tokyo, his only asset was a knowledge of monomers and their polymerization. He was able to secure help from another technocrat, Hiroshi Yoshioka, who had several ideas on polymerization, based on certain algorithms that worked paradoxically, like the hydrogen-oxygen combination that makes water. Hydrogen and oxygen are both flammable, but when they are combined as H2O they produce water, which works as a fire extinguisher! Similarly, several cytotoxic monomers, when polymerized, become cell friendly and could allow even some of the most difficult cellular organisms and explant cells from tissue to grow in the lab! This was the eureka moment, as their scaffold could grow stem cells at a time when the entire world was investigating stem cell research. But the joy was short lived as they realized their invention would need huge investments in time and money to become a success.

That’s when they began to look at things differently. They looked into cells of animal and plant origin both in the same platform. They found that the cell-friendly polymer had a great water conservation capacity, and their focus shifted to agriculture. This has earned them revenue, and it has also kept their other researches progressing. Using their technology, dry farmland in Arabian deserts has started producing strawberries and tomatoes!

Continue reading